• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


             

OSB Lead-Continued Follow-up of Premarket Cohort


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Application Number P100018 / PAS001
Current Plan Approved 06/27/2011
Study Name OSB Lead-Continued Follow-up of Premarket Cohort
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description Single arm prospective cohort
Study Population Description Pipeline Embolic Device pivotal study cohort and the (device and control continued access cohort follow up. These were patients group) with wide-necked intracranial aneurysms in the internal

carotid artery from the petrous to the superior hypophyseal segments.

Sample Size (no. 134 subjects, 2-subgroup analyses by aneurysm location

study sites and and by hypertension status

patients)

Data Collection Ipsilateral stroke or neurovascular death Secondary: complete occlusion of treated aneurysm,

stenosis of the parent artery in PED, and device-related adverse events.

Follow-up Visits and Length of Follow-up 5 years


OSB Lead-Continued Follow-up of Premarket Cohort Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
six month report 10/05/2011 10/05/2011 On Time
one year report 04/05/2012 05/23/2012 Overdue/Received
18 month report 10/04/2012 10/04/2012 On Time
two year report 04/05/2013 04/23/2013 Overdue/Received
three year report 04/05/2014 04/07/2014 Overdue/Received
four year report 04/05/2015 04/06/2015 Overdue/Received
60 month report (5 year) 05/23/2016 05/23/2016 On Time
six year report 05/23/2017    


Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Related Links

-
-